APL-130277: Clinical Trials

3 trials of APL-130277, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow APL-130277: new trials by email Literature Review of APL-130277 trials Research Report on APL-130277

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
APL-130277, APO-go, Apokyn - Parkinson Disease
Phase 2CompletedSumitomo Pharma America, Inc.82017-08-222020-08-13
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
APL-130277, Placebo, Moxifloxacin - Parkinson's Disease, Off Episodes of Parkinson Disease
Phase 2CompletedSumitomo Pharma America, Inc.482017-08-032020-08-10
A Study to Examine APL-130277 in Patients With Parkinson's Disease
APL-130277 - Parkinson's Disease
Phase 2CompletedSumitomo Pharma America, Inc.202014-08-312020-07-30

Conditions studied

Parkinson Disease (3)

Sponsors

Sumitomo Pharma America, Inc. (3)

Countries

United States (3)  ·  Italy (1)

Results publications

PMID 33991326, PMID 35899977

NIH funding

2016 (1)